Lonza Group (LTS:0QNO) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QNO Lonza Group Ltd LTS:0QNO
81 GF Score
Price CHF587.07
GF Value CHF579.87
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Lonza Group Net Loan?

Net Loan only applies to banks and insurance companies.

LTS:0QNO
81GF Score
Lonza Group Ltd LTS:0QNO
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Lonza Group (LTS:0QNO) Overvalued in 2026?

Based on GuruFocus' analysis, Lonza Group stock appears to be overvalued. The current stock price of CHF587.07 is trading 1.2% above its estimated GF Value™ of CHF579.87. GuruFocus considers Lonza Group to be Fairly Valued.

Key valuation signals for LTS:0QNO:

  • Net Loan:
  • GF Value™: CHF579.87 vs. price of CHF587.07 (1.2% above fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the LTS:0QNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lonza Group Business Description

Address Muenchensteinerstrasse 38, Basel, CHE, 4002
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
81GF Score

Get the complete analysis for LTS:0QNO

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF587.07
Price
CHF579.87
GF Value